Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Ruizhi He"'
Autor:
Da Wang, Junsheng Chen, Guanhua Wu, Fei Xiong, Wenzheng Liu, Qi Wang, Yiyang Kuai, Wenhua Huang, Yongqiang Qi, Bing Wang, Ruizhi He, Yongjun Chen
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-18 (2024)
Abstract Background Cholangiocarcinoma (CCA) is a highly malignant, rapidly progressing tumor of the bile duct. Owing to its chemoresistance, it always has an extremely poor prognosis. Therefore, detailed elucidation of the mechanisms of chemoresista
Externí odkaz:
https://doaj.org/article/1bad50f6a60849b79a8adb98f1b8a30b
Autor:
Feng Peng, Ruizhi He, Yuhui Liu, Yu Xie, Guangbing Xiong, Xu Li, Min Wang, Chunle Zhao, Hang Zhang, Simiao Xu, Renyi Qin
Publikováno v:
Non-coding RNA Research, Vol 9, Iss 4, Pp 1098-1110 (2024)
Cholangiocarcinoma is one of the most lethal human cancers, and chemotherapy failure is a major cause of recurrence and poor prognosis. We previously demonstrated that miR-200 family members are downregulated in clinical samples of cholangiocarcinoma
Externí odkaz:
https://doaj.org/article/51344991e4124770945624e795c76798
Autor:
Jun Gong, Yuhui Liu, Wenjia Wang, Ruizhi He, Qilong Xia, Lin Chen, Chunle Zhao, Yang Gao, Yongkang Shi, Yu Bai, Yangwei Liao, Qi Zhang, Feng Zhu, Min Wang, Xu Li, Renyi Qin
Publikováno v:
Advanced Science, Vol 10, Iss 29, Pp n/a-n/a (2023)
Abstract Ferroptosis, an iron‐dependent form of regulated cell death driven by excessive accumulation of lipid peroxides, has become a promising strategy in cancer treatment. Cancer cells exploit antioxidant proteins, including Ferroptosis Suppress
Externí odkaz:
https://doaj.org/article/135a3e2df28846809f66882744b2c577
Autor:
Xiuhui Shi, Min Wang, Yuqing Zhang, Xingjun Guo, Mingyang Liu, Zhijun Zhou, Yan Zhao, Ruizhi He, Yang Gao, Yuhui Liu, Shutao Pan, Min Zhou, Chunle Zhao, Taoyuan Yin, Xu Li, Hebin Wang, Jingxuan Yang, Feng Zhu, Min Li, Renyi Qin
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104352- (2022)
Summary: Background: Epidermal growth factor receptor (EGFR) is an essential target for cancer treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic cancer therapy. Here, we showed the underlying mechanism of tumo
Externí odkaz:
https://doaj.org/article/4c15ca43bf3b455688e4d43ca1187f31
Autor:
Min Wang, Jun Liu, Yan Zhao, Ruizhi He, Xiaodong Xu, Xingjun Guo, Xu Li, Simiao Xu, Ji Miao, Jianpin Guo, Hang Zhang, Jun Gong, Feng Zhu, Rui Tian, Chengjian Shi, Feng Peng, Yechen Feng, Shuo Yu, Yu Xie, Jianxin Jiang, Min Li, Wenyi Wei, Chuan He, Renyi Qin
Publikováno v:
Molecular Cancer, Vol 19, Iss 1, Pp 1-15 (2020)
Abstract Background Pancreatic cancer is one of the most lethal human cancers. N 6-methyladenosine (m6A), a common eukaryotic mRNA modification, plays critical roles in both physiological and pathological processes. However, its role in pancreatic ca
Externí odkaz:
https://doaj.org/article/7b43f90622754d36a7c0300e57b2b7ae
Autor:
Guangbing Xiong, Shutao Pan, Jikuan Jin, Xiaoxiang Wang, Ruizhi He, Feng Peng, Xu Li, Min Wang, Jianwei Zheng, Feng Zhu, Renyi Qin
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Pancreatic cancer (PC) is a highly malignant disease characterized by insidious onset, rapid progress, and poor therapeutic effects. The molecular mechanisms associated with PC initiation and progression are largely insufficient, hampering the exploi
Externí odkaz:
https://doaj.org/article/3fc790bf2ab743c0b428745c11014bb5
Autor:
Ruizhi He, Min Wang, Chunle Zhao, Ming Shen, Yahong Yu, Li He, Yan Zhao, Hua Chen, Xiuhui Shi, Min Zhou, Shutao Pan, Yuhui Liu, Xingjun Guo, Xu Li, Renyi Qin
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-14 (2019)
Abstract Background Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, with a 5-year survival rate of less than 8%. The complicated tumor microenvironment, particularly TGF-β, provides possible convenience for the progression of
Externí odkaz:
https://doaj.org/article/b664d2ed597140cfadc84678f0422353
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background Pancreatic cancer is a highly malignant tumor with a poor prognosis. Chemotherapy such as gemcitabine is still an important treatment. Gemcitabine (Gem) may prolong survival time and delay the development of recurrent disease afte
Externí odkaz:
https://doaj.org/article/7bf82abb030046f989c6f86cd051fd0f
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
Pancreatic cancer (PC) is one of the most lethal diseases, and effective treatment of PC patients remains an enormous challenge. Rocaglamide A (Roc-A), a bioactive molecule extracted from the plant Aglaia elliptifolia, has aroused considerable attent
Externí odkaz:
https://doaj.org/article/0b85dac9f6034b53800e365e37017039
Publikováno v:
International Journal of Surgery. 109:660-669